Let's review the charts and indicators to see what they are showing today.
M&A activity has generally slowed.
Black-market vaping has made the entire cannabis group toxic.
Both are proud they dodged the Twitter bullet. But, in retrospect, was it really a bullet?
A dividend hike and a big buyback authorization by Mr. Softee should produce value for shareholders.
The cloud stock's results weren't great, but were nothing close to the FedEx disaster.
After a sprint higher in the IT company's shares in recent days, traders and investors might do well to wait for a temporary pullback to pick up the stock.
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
The cybersecurity name fired off some punches at the competition and picked up another bolt-on acquisition amid earnings.
Shares of the provider of network security platforms could bump into a resistance zone after a strong start.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
CRM shouldn't be sagging with the broader tech sector.
I see VMW trading in the high $130s and my engine gets running.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Salesforce is characteristically sustaining strength despite a heap of headwinds.
Let's go back again to charts of VIAB.
Nvidia's second-quarter profits were well below its year-ago earnings but were nicely ahead of analyst expectations.
Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.
Sellers of the beverage company's shares have been acting more aggressively than buyers in recent weeks.
A drop in shares doesn't necessarily mean it's time to turn the channel on Viacom, as details of expected merger with CBS will prove 'paramount.'
Armed with Showtime, lots of cartoons and other mainstream shows, the CBS/Viacom merger appears to fit in between Disney Plus' family-friendly shows and Netflix's darker offerings -- but expect some drama for investors.
Only at a discount, so if there is disappointment there is some wiggle room for maneuver.
The technical signs do not instill a ton of confidence, though a bit of strength could change the outlook.
Viacom shareholders may finally be rewarded this week for their patience.
Uber's crash on earnings does not mean the stock is totaled according to analysts covering the stock.
Disney's dive after earnings could open up a buying opportunity to investors that missed the recent run.
The food giant is one of the few stocks holding its ground on Monday morning; here's why.